IN2012DN01984A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01984A
IN2012DN01984A IN1984DEN2012A IN2012DN01984A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A IN 1984DEN2012 A IN1984DEN2012 A IN 1984DEN2012A IN 2012DN01984 A IN2012DN01984 A IN 2012DN01984A
Authority
IN
India
Prior art keywords
tfpi
aptamers
bind
disorders
nostics
Prior art date
Application number
Other languages
English (en)
Inventor
G Schaub Robert
Mcginness Kathleen
Nelson Jennifer
Genga Ryan
Waters Emily
C Kurz Jeffrey
L Diener John
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int filed Critical Baxter Int
Publication of IN2012DN01984A publication Critical patent/IN2012DN01984A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
IN1984DEN2012 2009-08-18 2010-08-17 IN2012DN01984A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23493909P 2009-08-18 2009-08-18
US35337410P 2010-06-10 2010-06-10
US36636210P 2010-07-21 2010-07-21
US36776610P 2010-07-26 2010-07-26
PCT/US2010/045797 WO2011022427A1 (en) 2009-08-18 2010-08-17 Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics

Publications (1)

Publication Number Publication Date
IN2012DN01984A true IN2012DN01984A (ja) 2015-07-24

Family

ID=43607310

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1984DEN2012 IN2012DN01984A (ja) 2009-08-18 2010-08-17

Country Status (17)

Country Link
US (1) US8252913B2 (ja)
EP (1) EP2467167B1 (ja)
JP (1) JP2013502218A (ja)
KR (1) KR20120061086A (ja)
CN (1) CN102869385A (ja)
AU (1) AU2010284329B2 (ja)
BR (1) BR112012003806A2 (ja)
CA (1) CA2770762A1 (ja)
CO (1) CO6531414A2 (ja)
ES (1) ES2655589T3 (ja)
IL (1) IL218048A0 (ja)
IN (1) IN2012DN01984A (ja)
MX (1) MX2012002133A (ja)
NZ (1) NZ598557A (ja)
RU (1) RU2012110221A (ja)
SG (1) SG178408A1 (ja)
WO (1) WO2011022427A1 (ja)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
US8361469B2 (en) 2008-12-22 2013-01-29 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
CA2827160A1 (en) * 2011-02-11 2012-08-16 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
ES2557633T3 (es) * 2011-06-08 2016-01-27 Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej Ribonucleasa H modificada por ingeniería específica de secuencia y el método para determinar la preferencia de secuencia de proteínas de unión de híbrido de ADN-ARN
US20130267584A1 (en) * 2012-03-22 2013-10-10 Baxter Healthcare S.A. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
EP3036542B1 (en) * 2013-06-21 2021-02-17 Imigene Inc. A method for assaying a blood sample obtained from a subject
EP3022228B1 (en) 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US9695424B2 (en) 2013-09-09 2017-07-04 Somalogic, Inc. PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
US11181534B2 (en) 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
EP3313991A4 (en) * 2015-06-23 2018-12-05 The Children's Hospital of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
US20170232079A1 (en) * 2015-10-06 2017-08-17 Kieu Hoang Method of manufacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
CN108368509B (zh) * 2015-12-04 2022-03-22 全药工业株式会社 改善了血中滞留性的抗il－17适体
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN115792231B (zh) * 2022-11-04 2023-07-25 中拓生物有限公司 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
AU757175B2 (en) 1997-09-05 2003-02-06 Regents Of The University Of California, The Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
DE69937223T3 (de) 1998-11-09 2011-05-05 Eiken Kagaku K.K. Verfahren zur synthese von nukleinsäuren
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
WO2003102212A2 (en) * 2002-05-31 2003-12-11 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor

Also Published As

Publication number Publication date
NZ598557A (en) 2013-08-30
IL218048A0 (en) 2012-04-30
AU2010284329A1 (en) 2012-03-29
JP2013502218A (ja) 2013-01-24
EP2467167B1 (en) 2017-08-16
CA2770762A1 (en) 2011-02-24
MX2012002133A (es) 2013-02-15
ES2655589T3 (es) 2018-02-20
KR20120061086A (ko) 2012-06-12
BR112012003806A2 (pt) 2016-11-16
SG178408A1 (en) 2012-03-29
EP2467167A4 (en) 2013-12-25
RU2012110221A (ru) 2013-09-27
CN102869385A (zh) 2013-01-09
EP2467167A1 (en) 2012-06-27
AU2010284329B2 (en) 2015-04-16
WO2011022427A1 (en) 2011-02-24
US20110098345A1 (en) 2011-04-28
US8252913B2 (en) 2012-08-28
CO6531414A2 (es) 2012-09-28

Similar Documents

Publication Publication Date Title
IN2012DN01984A (ja)
MX2012011771A (es) Aptameros para beta-ngf y su uso en el tratamiento de enfermedades y trastornos mediados por beta-ngf.
AU2018236800B2 (en) DNA-PK inhibitors
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
WO2012174487A3 (en) Bromodomain inhibitors and uses thereof
WO2012151512A3 (en) Bromodomain inhibitors and uses thereof
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
WO2012075383A3 (en) Bromodomain inhibitors and uses thereof
PH12016500182A1 (en) Anti-activin a antibodies and uses thereof
WO2013151736A3 (en) In vivo production of proteins
MY169987A (en) Selective pi3k delta inhibitors
PH12014501108A1 (en) Anti-il-36r antibodies
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012138487A3 (en) Oligonucleotide modulation of splicing
EP2590671A4 (en) IMMUNOGLOBULINS WITH DOUBLE VARIABLE DOMAIN AND USES THEREOF
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
WO2010083207A3 (en) Protein kinase c inhibitors and uses thereof
MX2013012053A (es) Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos.
SG10201804817TA (en) Delayed release compositions of linaclotide
WO2013055899A3 (en) Compositions useful in treating nephropathy and methods for preparation of same
MX347734B (es) Anticuerpos anti-s100a4 y usos aplicaciones terapéuticas.
WO2012125981A3 (en) Raf kinase inhibitors
WO2014159669A3 (en) Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions
MX344189B (es) Formulaciones de mazindol.